Institution
Georgetown University
Education•Washington D.C., District of Columbia, United States•
About: Georgetown University is a education organization based out in Washington D.C., District of Columbia, United States. It is known for research contribution in the topics: Population & Cancer. The organization has 23377 authors who have published 43718 publications receiving 1748598 citations. The organization is also known as: GU & Georgetown.
Topics: Population, Cancer, Breast cancer, Health care, Politics
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Ipilimumab, an antibody targeting CTLA-4, appears to restore tumor immunity at the priming phase, whereas anti-PD-1/PD-L1 antibodies restore immune function in the tumor microenvironment, and antibody-based interventions targeting CTL antigen 4 and programmed cell death protein 1 produce significant anti-tumor activity with considerably less toxicity.
Abstract: Despite extensive investigation over the past three decades, cancer immunotherapy has produced limited success, with few agents achieving approval by the Food and Drug Administration and even the most effective helping only a minority of patients, primarily with melanoma or renal cancer. In recent years, immune checkpoints that maintain physiologic self-tolerance have been implicated in the down-regulation of anti-tumor immunity. Efforts to restore latent anti-tumor immunity have focused on antibody-based interventions targeting CTL antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) on T lymphocytes and its principal ligand (PD-L1) on tumor cells. Ipilimumab, an antibody targeting CTLA-4, appears to restore tumor immunity at the priming phase, whereas anti-PD-1/PD-L1 antibodies restore immune function in the tumor microenvironment. Although ipilimumab can produce durable long-term responses in patients with advanced melanoma, it is associated with significant immune-related toxicities. By contrast, antibodies targeting either PD-1 or PD-L1 have produced significant anti-tumor activity with considerably less toxicity. Activity was seen in patients with melanoma and renal cancer, as well as those with non-small-cell lung, bladder and head and neck cancers, tumors not previously felt to be sensitive to immunotherapy. The tolerability of PD-1-pathway blockers and their unique mechanism of action have made them ideal backbones for combination regimen development. Combination approaches involving cytotoxic chemotherapy, anti-angiogenic agents, alternative immune-checkpoint inhibitors, immunostimulatory cytokines and cancer vaccines are currently under clinical investigation. Current efforts focus on registration trials of single agents and combinations in various diseases and disease settings and identifying predictive biomarkers of response.
308 citations
••
TL;DR: This paper examined the response of investors and analysts of non-announcing firms to the earnings report of the first announcers in the industry and found that the error in the first announcer's forecast was informative about the errors in contemporaneous earnings forecasts of subsequent announcers.
Abstract: In this article I examine the response of investors and analysts of nonannouncing firms to the earnings report of the first announcers in the industry. The error in the earnings forecast of the first announcer is found to be informative about the errors in the contemporaneous earnings forecasts of subsequent announcers in the industry. However, investors and analysts do not appear to fully incorporate the information from the first announcers’ news in their revised earnings expectations for subsequent announcers. This apparent underreaction to the first announcers’ news leads to predictable stock returns for subsequent announcers in the days following the first announcement. Results of this study can be seen as further evidence of investor and analyst underreaction to publicly available information.
308 citations
••
TL;DR: An MSI assay that uses data from a commercially available next‐generation sequencing (NGS) panel to determine MSI status is developed and offers distinct data for treatment decisions regarding immune checkpoint inhibitors, in addition to the data available from TMB and PD‐L1.
Abstract: Microsatellite instability (MSI) testing identifies patients who may benefit from immune checkpoint inhibitors. We developed an MSI assay that uses data from a commercially available next-generation sequencing (NGS) panel to determine MSI status. The assay is applicable across cancer types and does not require matched samples from normal tissue. Here, we describe the MSI-NGS method and explore the relationship of MSI with tumor mutational burden (TMB) and PD-L1. MSI examined by PCR fragment analysis and NGS was compared for 2189 matched cases. Mismatch repair status by immunohistochemistry was compared to MSI-NGS for 1986 matched cases. TMB was examined by NGS, and PD-L1 was determined by immunohistochemistry. Among 2189 matched cases that spanned 26 cancer types, MSI-NGS, as compared to MSI by PCR fragment analysis, had sensitivity of 95.8% (95% confidence interval [CI] 92.24, 98.08), specificity of 99.4% (95% CI 98.94, 99.69), positive predictive value of 94.5% (95% CI 90.62, 97.14), and negative predictive value of 99.2% (95% CI, 98.75, 99.57). High MSI (MSI-H) status was identified in 23 of 26 cancer types. Among 11,348 cases examined (including the 2189 matched cases), the overall rates of MSI-H, TMB-high, and PD-L1 positivity were 3.0%, 7.7%, and 25.4%, respectively. Thirty percent of MSI-H cases were TMB-low, and only 26% of MSI-H cases were PD-L1 positive. The overlap between TMB, MSI, and PD-L1 differed among cancer types. Only 0.6% of the cases were positive for all three markers. MSI-H status can be determined by NGS across cancer types. MSI-H offers distinct data for treatment decisions regarding immune checkpoint inhibitors, in addition to the data available from TMB and PD-L1.
307 citations
••
Medical University of South Carolina1, Lahey Hospital & Medical Center2, Wake Forest University3, University of Florida4, Autonomous University of Madrid5, University of California, San Francisco6, Université de Montréal7, University of Glasgow8, University of Paris9, McMaster University10, Bristol-Myers Squibb11, University of Wisconsin-Madison12, Georgetown University13
TL;DR: Sixty percent of the deaths in patients with HFPEF were cardiovascular, with sudden death and heart failure death being the most common and treatment with irbesartan did not affect overall mortality or the distribution of mode-specific mortality rates.
Abstract: Background— The mode of death has been well characterized in patients with heart failure and a reduced ejection fraction; however, less is known about the mode of death in patients with heart failure and a preserved ejection fraction (HFPEF). The purpose of this study was to examine the mode of death in patients with HFPEF enrolled in the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial and to determine whether irbesartan altered the distribution of mode of death in HFPEF. Methods and Results— All deaths were reviewed by a clinical end-point committee, and the mode of death was assigned by consensus of the members. The annual mortality rate was 5.2% in the I-Preserve trial. There were no significant differences in mortality rate between the placebo and irbesartan groups. The mode of death was cardiovascular in 60% (including 26% sudden, 14% heart failure, 5% myocardial infarction, and 9% stroke), noncardiovascular in 30%, and unknown in 10%. There were no differences i...
307 citations
••
University of California, San Francisco1, University of Texas MD Anderson Cancer Center2, University of North Carolina at Chapel Hill3, University of Pennsylvania4, Lawrence Berkeley National Laboratory5, Oregon Health & Science University6, Boston University7, Memorial Sloan Kettering Cancer Center8, University of Alabama9, Albert Einstein College of Medicine10, University of Southern California11, University of Washington12, Georgetown University13, University of Chicago14, Yale University15, New York University16
TL;DR: Categorization of breast cancer by molecular signatures enhanced the ability of pCR to predict improvement in RFS compared to the population as a whole, and molecular markers improve prediction of RFS by identifying additional patients with excellent prognosis within the no pCR group.
Abstract: Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥ 3 cm tumors by using early imaging and molecular signatures, with outcomes of pathologic complete response (pCR) and RFS. The current analysis was performed using data from patients who had molecular profiles and did not receive trastuzumab. The various molecular classifiers tested were highly correlated. Categorization of breast cancer by molecular signatures enhanced the ability of pCR to predict improvement in RFS compared to the population as a whole. In multivariate analysis, the molecular signatures that added to the ability of HR and HER2 receptors, clinical stage, and pCR in predicting RFS included 70-gene signature, wound healing signature, p53 mutation signature, and PAM50 risk of recurrence. The low risk signatures were associated with significantly better prognosis, and also identified additional patients with a good prognosis within the no pCR group, primarily in the hormone receptor positive, HER-2 negative subgroup. The I-SPY 1 population is enriched for tumors with a poor prognosis but is still heterogeneous in terms of rates of pCR and RFS. The ability of pCR to predict RFS is better by subset than it is for the whole group. Molecular markers improve prediction of RFS by identifying additional patients with excellent prognosis within the no pCR group.
306 citations
Authors
Showing all 23641 results
Name | H-index | Papers | Citations |
---|---|---|---|
Cyrus Cooper | 204 | 1869 | 206782 |
David Cella | 156 | 1258 | 106402 |
Carl H. June | 156 | 835 | 98904 |
Ichiro Kawachi | 149 | 1216 | 90282 |
Judy Garber | 147 | 756 | 79157 |
Bernard J. Gersh | 146 | 973 | 95875 |
Edward G. Lakatta | 146 | 858 | 88637 |
Eugene C. Butcher | 146 | 446 | 72849 |
Mark A. Rubin | 145 | 699 | 95640 |
Richard B. Devereux | 144 | 962 | 116403 |
Robert H. Purcell | 139 | 666 | 70366 |
Eric P. Winer | 139 | 751 | 71587 |
Richard L. Huganir | 137 | 425 | 61023 |
Rasmus Nielsen | 135 | 556 | 84898 |
Henry T. Lynch | 133 | 925 | 86270 |